Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

Sponsor
Swedish Orphan Biovitrum
Study ID
NCT07746895
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • C3 Glomerulopathy (C3G)
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pegcetacoplan — DRUG
    Solution for infusion for subcutaneous use according to drug use in the real world.

Study Details

The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.

Key Dates

First listed
Aug 5, 2026
Start date
Jul 9, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2031
Completion
Jan 31, 2032

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Single arm

Primary Outcome Measure

Achieving urine protein-to-creatinine ratio (UPCR) of <1 g/g [ Time Frame: at 6 months after starting pegcetacoplan treatment ]

Central Contacts